此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

eRT Remote Health Monitoring

2020年4月29日 更新者:Christopher B Cooper, MD、University of California, Los Angeles

Feasibility and Cost Effectiveness of Physiological Monitoring at Home in COPD Patients

Remote Health Monitoring (RHM) is the assessment of one's own symptoms at home between doctor visits, using things like at-home breathing tests, electronic diaries to answer questionnaires, and other monitoring devices. The hypothesis of this study is that the health and quality of life of people with COPD who do RHM for one year will be better than people with COPD who do not do RHM. Subjects who are at least 40 years old, have been diagnosed with chronic obstructive pulmonary disease (COPD), also known as chronic bronchitis or emphysema, and are current or former smokers will be invited to participate. This study is paid for by eResearch Technology (eRT).

Subjects will complete 2 visits at UCLA, separated by one year of RHM. All subjects will participate in RHM. RHM will involve daily monitoring at home using a few electronic devices: blood oxygen levels, symptoms, medication use, breathing tests, and activity monitoring. Visits will include physical exam and medical history, ECG, questionnaires, breathing tests, and exercise tests.

研究概览

研究类型

介入性

注册 (实际的)

17

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Los Angeles、California、美国、90095
        • UCLA David Geffen School of Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age >40 years.
  • Clinical diagnosis of moderate to severe COPD in accordance with the definition of the American Thoracic Society (ATS).9
  • Smoking history >10 pack-years.
  • Postbronchodilator FEV1/FVC<70% and FEV1<70% based on NHANES III reference values
  • Domestic situation felt to be supportive of remote health monitoring.
  • Ability to give informed consent.

Exclusion Criteria:

  • Clinical diagnosis of asthma.
  • Pulmonary disease other than COPD (e.g., lung cancer, sarcoidosis, active tuberculosis, bronchiectasis, pulmonary fibrosis, cystic fibrosis, or alpha-1-antitrypsin deficiency) or had lung volume reduction.
  • Any other active disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation (e.g. unstable cardiovascular disease, renal failure, stroke).
  • Previously diagnosed cancer is considered a significant disease unless it is in complete remission for 2 years at the initial visit.
  • Any other disease that is life-threatening and carries a prognosis less than two years that, in the opinion of the investigator, is likely to influence the clinical course during the conduct of this trial.
  • Myocardial infarction within 6 weeks of enrolment.
  • Use of long-term oxygen therapy (LTOT) prescribed for greater than 12 hours a day.
  • A known or suspected history of drug or alcohol abuse within 2 years prior to the initial visit.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Remote Health Monitoring
Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team. Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team). Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Compliance with daily RHM
大体时间:1 year
Compliance with daily RHM as a percentage of study days
1 year
Integrity of spirometric data
大体时间:1 year
Integrity of the spirometric data in terms of the standard American Thoracic Society and European Respiratory Society criteria for acceptability and repeatability.
1 year

次要结果测量

结果测量
措施说明
大体时间
就诊次数
大体时间:1年
1年
Rate of adoption of RHM
大体时间:1 year
Time it takes for subjects to become compliant with daily RHM
1 year
Treatment adherence
大体时间:1 year
Treatment adherence in terms of percentage of days prescribed treatment* is taken (* treatment separate from study, prescribed by personal physician)
1 year
Time to first COPD exacerbation
大体时间:1 year
Time to first COPD exacerbation as defined by standard criteria.
1 year
Number of COPD exacerbations per year
大体时间:1 year
1 year
Proportion of subjects experiencing one or more exacerbations
大体时间:1 year
1 year
Mean daily FEV1
大体时间:1 year
1 year
Mean daily IC
大体时间:1 year
1 year
Mean daily activity level
大体时间:1 year
1 year
Mean daily SpO2
大体时间:1 year
1 year
Daily symptom scores
大体时间:1 year
1 year
Number of emergency department visits
大体时间:1 year
1 year
Number of hospitalizations
大体时间:1 year
1 year
Number of days spent in hospital
大体时间:1 year
1 year
Health care costs
大体时间:1 year
Inferred health care costs using a standard cost framework model
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2012年1月1日

初级完成 (实际的)

2014年8月20日

研究完成 (实际的)

2014年8月20日

研究注册日期

首次提交

2011年12月16日

首先提交符合 QC 标准的

2011年12月16日

首次发布 (估计)

2011年12月20日

研究记录更新

最后更新发布 (实际的)

2020年5月1日

上次提交的符合 QC 标准的更新

2020年4月29日

最后验证

2020年4月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Remote Health Monitoring的临床试验

3
订阅